RLFDDA: a meta-path based graph representation learning model for drug-disease association prediction

PCDA-HNMP: Predicting circRNA-disease association using heterogeneous network and meta-path

Increasing amounts of experimental studies have shown that circular RNAs (circRNAs) play important regulatory roles in human diseases through interactions with related microRNAs (miRNAs). CircRNAs have become new potential disease biomarkers and therapeutic targets. Predicting circRNA-disease association (CDA) is of great significance for exploring the pathogenesis of complex diseases, which can improve the diagnosis level of diseases and promote the targeted therapy of diseases. However, determination of CDAs through traditional clinical trials is usually time-consuming and expensive. Computational methods are now alternative ways to predict CDAs. In this study, a new computational method, named PCDA-HNMP, was designed. For obtaining informative features of circRNAs and diseases, a heterogeneous network was first constructed, which defined circRNAs, mRNAs, miRNAs and diseases as nodes and associations between them as edges. Then, a deep analysis was conducted on the heterogeneous network by extracting meta-paths connecting to circRNAs (diseases), thereby mining hidden associations between various circRNAs (diseases). These associations constituted the meta-path-induced networks for circRNAs and diseases. The features of circRNAs and diseases were derived from the aforementioned networks via mashup. On the other hand, miRNA-disease associations (mDAs) were employed to improve the model's performance. miRNA features were yielded from the meta-path-induced networks on miRNAs and circRNAs, which were constructed from the meta-paths connecting miRNAs and circRNAs in the heterogeneous network. A concatenation operation was adopted to build the features of CDAs and mDAs. Such representations of CDAs and mDAs were fed into XGBoost to set up the model. The five-fold cross-validation yielded an area under the curve (AUC) of 0.9846, which was better than those of some existing state-of-the-art methods. The employment of mDAs can really enhance the model's performance and the importance analysis on meta-path-induced networks shown that networks produced by the meta-paths containing validated CDAs provided the most important contributions.

EGeRepDR: An enhanced genetic-based representation learning for drug repurposing using multiple biomedical sources

MOTIVATION

Drug repurposing (DR) is an imminent approach for identifying novel therapeutic indications for the available drugs and discovering novel drugs for previously untreatable diseases. Nowadays, DR has major attention in the pharmaceutical industry due to the high cost and time of launching new drugs to the market through traditional drug development. DR task majorly depends on genetic information since the drugs revert the modified Gene Expression (GE) of diseases to normal. Many of the existing studies have not considered the genetic importance of predicting the potential candidates.

METHOD

We proposed a novel multimodal framework that utilizes genetic aspects of drugs and diseases such as genes, pathways, gene signatures, or expression to enhance the performance of DR using various data sources. Firstly, the heterogeneous biological network (HBN) is constructed with three types of nodes namely drug, disease, and gene, and 4 types of edges similarities (drug, gene, and disease), drug-gene, gene-disease, and drug-disease. Next, a modified graph auto-encoder (GAE*) model is applied to learn the representation of drug and disease nodes using the topological structure and edge information. Secondly, the HBN is enhanced with the information extracted from biomedical literature and ontology using a novel semi-supervised pattern embedding-based bootstrapping model and novel DR perspective representation learning respectively to improve the prediction performance. Finally, our proposed system uses a neural network model to generate the probability score of drug-disease pairs.

RESULTS

We demonstrate the efficiency of the proposed model on various datasets and achieved outstanding performance in 5-fold cross-validation (AUC = 0.99, AUPR = 0.98). Further, we validated the top-ranked potential candidates using pathway analysis and proved that the known and predicted candidates share common genes in the pathways.

Inferring drug-disease associations by a deep analysis on drug and disease networks

Drugs, which treat various diseases, are essential for human health. However, developing new drugs is quite laborious, time-consuming, and expensive. Although investments into drug development have greatly increased over the years, the number of drug approvals each year remain quite low. Drug repositioning is deemed an effective means to accelerate the procedures of drug development because it can discover novel effects of existing drugs. Numerous computational methods have been proposed in drug repositioning, some of which were designed as binary classifiers that can predict drug-disease associations (DDAs). The negative sample selection was a common defect of this method. In this study, a novel reliable negative sample selection scheme, named RNSS, is presented, which can screen out reliable pairs of drugs and diseases with low probabilities of being actual DDAs. This scheme considered information from k-neighbors of one drug in a drug network, including their associations to diseases and the drug. Then, a scoring system was set up to evaluate pairs of drugs and diseases. To test the utility of the RNSS, three classic classification algorithms (random forest, bayes network and nearest neighbor algorithm) were employed to build classifiers using negative samples selected by the RNSS. The cross-validation results suggested that such classifiers provided a nearly perfect performance and were significantly superior to those using some traditional and previous negative sample selection schemes.